• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硬脂酰辅酶A去饱和酶-1的高通量闪烁邻近分析

High-throughput scintillation proximity assay for stearoyl-CoA desaturase-1.

作者信息

Tawa Paul, Falgueyret Jean-Pierre, Guiral Sebastien, Isabel Elise, Powell David A, Zuck Paul, Skorey Kathryn

机构信息

Merck Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, Québec, Canada.

出版信息

J Biomol Screen. 2011 Jun;16(5):506-17. doi: 10.1177/1087057111399436. Epub 2011 Mar 15.

DOI:10.1177/1087057111399436
PMID:21406617
Abstract

Stearoyl-CoA desaturase (SCD) catalyzes the synthesis of monounsaturated fatty acids and has been implicated in a number of disease states, including obesity and diabetes. To find small-molecule inhibitor leads, a high-throughput scintillation proximity assay (SPA) was developed using the hydrophobic binding characteristics of a glass microsphere scintillant bead to capture SCD1 from a crude lysate of recombinant SCD1 in Sf9 lysate coupled with the strong binding characteristics of an azetidine compound ([(3)H]AZE). The SPA assay was stable over 24 h and could detect compounds with micromolar to nanomolar potencies. A robust 1536-well high-throughput screening assay was developed with good signal-to-noise ratio (10:1) and excellent Z' factor (0.8). A screening collection of 1.6 million compounds was screened at 11 µM, and approximately 7700 compounds were identified as initial hits, exhibiting at least 35% inhibition of [(3)H]AZE binding. Further screening and confirmation with an SCD enzyme activity assay led to a number of new structural leads for inhibition of the enzyme. The SPA assay complements the enzyme activity assay for SCD1 as a tool for the discovery of novel leads in drug discovery.

摘要

硬脂酰辅酶A去饱和酶(SCD)催化单不饱和脂肪酸的合成,并与包括肥胖症和糖尿病在内的多种疾病状态有关。为了寻找小分子抑制剂先导物,利用玻璃微球闪烁珠的疏水结合特性,从杆状病毒表达系统(Sf9)裂解物中重组SCD1的粗裂解物中捕获SCD1,并结合氮杂环丁烷化合物([³H]AZE)的强结合特性,开发了一种高通量闪烁邻近分析(SPA)。该SPA分析在24小时内稳定,能够检测出具有微摩尔至纳摩尔效力的化合物。开发了一种稳健的1536孔高通量筛选分析,具有良好的信噪比(10:1)和出色的Z'因子(0.8)。以11µM的浓度对160万种化合物的筛选库进行筛选,约7700种化合物被鉴定为初始命中物,对[³H]AZE结合表现出至少35%的抑制作用。通过SCD酶活性分析进一步筛选和确认,得到了一些抑制该酶的新结构先导物。作为药物发现中发现新先导物的工具,SPA分析补充了SCD1的酶活性分析。

相似文献

1
High-throughput scintillation proximity assay for stearoyl-CoA desaturase-1.硬脂酰辅酶A去饱和酶-1的高通量闪烁邻近分析
J Biomol Screen. 2011 Jun;16(5):506-17. doi: 10.1177/1087057111399436. Epub 2011 Mar 15.
2
Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.利用大鼠肝微粒体、氘标记的硬脂酰辅酶A和质谱法开发一种用于硬脂酰辅酶A去饱和酶的高通量筛选测定法。
Anal Chim Acta. 2008 Oct 3;627(1):105-11. doi: 10.1016/j.aca.2008.04.017. Epub 2008 Apr 15.
3
Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.一种用于定量细胞硬脂酰辅酶A去饱和酶活性的新型液相色谱/质谱方法的开发。
Anal Chim Acta. 2008 Oct 3;627(1):99-104. doi: 10.1016/j.aca.2008.05.012. Epub 2008 May 15.
4
Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors.作为强效系统性分布的硬脂酰辅酶 A 去饱和酶抑制剂,氮杂环丁基吡啶并哒嗪的生物学活性和临床前疗效。
Bioorg Med Chem Lett. 2011 Jan 1;21(1):479-83. doi: 10.1016/j.bmcl.2010.10.107. Epub 2010 Oct 26.
5
A novel assay of cellular stearoyl-CoA desaturase activity of primary rat hepatocytes by HPLC.用 HPLC 法测定原代大鼠肝细胞中细胞硬脂酰辅酶 A 去饱和酶活性的新方法。
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 15;878(26):2427-32. doi: 10.1016/j.jchromb.2010.08.002. Epub 2010 Aug 10.
6
Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors.新型、强效、选择性且代谢稳定的硬脂酰辅酶A去饱和酶(SCD)抑制剂。
Bioorg Med Chem Lett. 2009 Apr 1;19(7):2048-52. doi: 10.1016/j.bmcl.2009.02.019. Epub 2009 Feb 8.
7
Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.口服生物可利用的肝脏选择性硬脂酰辅酶A去饱和酶(SCD)抑制剂。
Bioorg Med Chem Lett. 2009 Jun 1;19(11):3050-3. doi: 10.1016/j.bmcl.2009.04.004. Epub 2009 Apr 8.
8
Stearoyl-CoA desaturase inhibitors: update on patented compounds.硬脂酰辅酶A去饱和酶抑制剂:专利化合物的最新情况
Expert Opin Ther Pat. 2009 Sep;19(9):1169-91. doi: 10.1517/13543770903061311.
9
Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).一种强效、口服生物利用度的 SCD 抑制剂(MF-438)的合成与生物活性。
Bioorg Med Chem Lett. 2010 Jan 15;20(2):499-502. doi: 10.1016/j.bmcl.2009.11.111. Epub 2009 Nov 26.
10
Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.强效、口服生物可利用的肝脏选择性硬脂酰辅酶A去饱和酶(SCD)抑制剂。
Bioorg Med Chem Lett. 2009 Aug 1;19(15):4070-4. doi: 10.1016/j.bmcl.2009.06.017. Epub 2009 Jun 13.

引用本文的文献

1
Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy.加速的自下而上药物设计平台助力发现用于癌症治疗的新型硬脂酰辅酶A去饱和酶1抑制剂。
Oncotarget. 2017 Oct 6;9(1):3-20. doi: 10.18632/oncotarget.21545. eCollection 2018 Jan 2.
2
T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time.T-3364366以纳摩尔级效力和数小时的驻留时间靶向Δ-5去饱和酶的去饱和酶结构域。
ACS Med Chem Lett. 2016 Aug 10;7(9):868-72. doi: 10.1021/acsmedchemlett.6b00241. eCollection 2016 Sep 8.